Wall Street Tea...'s  Instablog

Wall Street Teacher
Send Message
Wall Street Teacher (a pseudonym) worked on Wall Street for several years in the fixed income area and now teaches and writes on financial topics (primarily regulation and markets). Current interests include the psychology of financial markets, the origins of chemistry/physics, synthetic... More
  • CorMedix Conference Call 0 comments
    Nov 19, 2013 9:46 AM | about stocks: CRMD

    This one might be worth listening to. The company has an approved product for sale in EU and is currently in discussions with FDA for a U.S. trial. Product is both safe and efficacious. Sales tem in EU has big pharma experience and has expertise in the dialysis space. IP issue is cloudy in EU but recent ruling(Prosl patent) should strengthen CRMD's hand. Short term catalysts include organic sales , likely partnering outside of EU(Middle East or Asia) and announcements re: approval of U.S. trial design. Longer term IP issue could also provide significant upside as existing provider is likely infringing on IP (see CorMedix S-1 for details).

    Please note that this issuer is not followed on the Street and remains quite illiquid. That said, valuation is exceptionally low in light of approved product status and potential market size of indications(dialysis, oncology, etc. ) for same. This is also a natural fit for the big two in U.S. dialysis space(Fresenius, DaVita) Long here and quite, quite hopeful.

    CorMedix to Report Third Quarter Financial Results on November 19, 2013

    BRIDGEWATER, N.J., Nov. 15, 2013 /PRNewswire/ -- CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardio-renal and infectious disease, today announced that the Company will report financial results for the third quarter ended September 30, 2013 after the close of trading on Tuesday, November 19, 2013. CorMedix has filed form 12b-25 with the U.S. Securities and Exchange Commission (the "SEC"), and as a result, the deadline for the Company to file its quarterly report on Form 10-Q with the SEC has been extended to November 19, 2013. CorMedix management will hold a conference call on Wednesday, November 20, 2013, at 9a.m. EST to discuss the results and provide an update on recent business developments. To access the call, please dial 1-866-866-1333 in the United States, and 1-404-260-1421 internationally. A live webcast of the conference call will also be available on the investor relations page of the Company's website at cormedix.com.

    Disclosure: I am long CRMD.

    Stocks: CRMD
Back To Wall Street Teacher's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


  • CorMedix: Making Progress In Both EU Commercial And U.S. Regulatory Fronts $CRMD http://seekingalpha.com/a/19v93
    Apr 14, 2014
  • Cormedix: An Interesting Play In The Catheter Care Space $CRMD http://seekingalpha.com/a/1582p
    Dec 31, 2013
  • I'm betting Europe works out. That's bad for the $ but good for gold. I guess the Germans rule the continent without having to fire a shot!
    Jun 4, 2012
More »

Latest Comments

Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.